Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs
Nucleoside, nucleotide, and base analogs have been in the clinic for decades to treat both
viral pathogens and neoplasms. More than 20% of patients on anticancer chemotherapy …
viral pathogens and neoplasms. More than 20% of patients on anticancer chemotherapy …
Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
M Karahoca, RL Momparler - Clinical epigenetics, 2013 - Springer
Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …
Decitabine-and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network
Mechanisms-of-resistance to decitabine and 5-azacytidine, mainstay treatments for myeloid
malignancies, require investigation and countermeasures. Both are nucleoside analog pro …
malignancies, require investigation and countermeasures. Both are nucleoside analog pro …
Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study
R Molokie, D Lavelle, M Gowhari, M Pacini… - PLoS …, 2017 - journals.plos.org
Background Sickle cell disease (SCD), a congenital hemolytic anemia that exacts terrible
global morbidity and mortality, is driven by polymerization of mutated sickle hemoglobin …
global morbidity and mortality, is driven by polymerization of mutated sickle hemoglobin …
Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates
X Gu, Q Ebrahem, RZ Mahfouz… - The Journal of …, 2018 - Am Soc Clin Investig
Nucleophosmin (NPM1) is among the most frequently mutated genes in acute myeloid
leukemia (AML). It is not known, however, how the resulting oncoprotein mutant NPM1 is …
leukemia (AML). It is not known, however, how the resulting oncoprotein mutant NPM1 is …
The emerging role of cytidine deaminase in human diseases: a new opportunity for therapy?
A Frances, P Cordelier - Molecular Therapy, 2020 - cell.com
The recycling activity of cytidine deaminase (CDA) within the pyrimidine salvage pathway is
essential to DNA and RNA synthesis. As such, CDA deficiency can lead to replicative stress …
essential to DNA and RNA synthesis. As such, CDA deficiency can lead to replicative stress …
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine …
RZ Mahfouz, A Jankowska, Q Ebrahem, X Gu… - Clinical cancer …, 2013 - AACR
Purpose: The cytidine analogs 5-azacytidine and decitabine, used to treat myelodysplastic
syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA …
syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA …
Chronic myelomonocytic leukemia diagnosis and management
Chronic myelomonocytic leukemia (CMML) is a rare, heterogeneous myeloid malignancy
classified as a myelodysplastic syndromes/myeloproliferative neoplasm (MDS/MPN) overlap …
classified as a myelodysplastic syndromes/myeloproliferative neoplasm (MDS/MPN) overlap …
Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells
FO Enane, Y Saunthararajah, M Korc - Cell death & disease, 2018 - nature.com
Chemotherapeutic drugs have a common intent to activate apoptosis in tumor cells.
However, master regulators of apoptosis (eg, p53, p16/CDKN2A) are frequently genetically …
However, master regulators of apoptosis (eg, p53, p16/CDKN2A) are frequently genetically …
Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
S Jueliger, J Lyons, S Cannito, I Pata, P Pata… - Epigenetics, 2016 - Taylor & Francis
Hepatocellular carcinoma (HCC) is a deadly malignancy characterized at the epigenetic
level by global DNA hypomethylation and focal hypermethylation on the promoter of tumor …
level by global DNA hypomethylation and focal hypermethylation on the promoter of tumor …